Fig. 6: Detection of Q183E and T1050N SNVs in SARS-CoV-2.
a Schematic workflow of the SARS-CoV-2 variant detection platform. b, c Box and whiskers plots of 60 clinical SARS-CoV-2 samples (30 BA.5.2 strains and 30 XBB-positive strains verified by NGS) were evaluated using the corresponding SNV crRNA and WT crRNA. NTC, non-target control. n = 3. ***P < 0.001, ****P < 0.0001; ns not significant. d, e Heatmap indicating the trans-cleavage activity of the Q183E or T1050N targets tested against the corresponding SNP crRNA or WT crRNA. The values in the heatmap represent the mean fluorescence value increase within 1 h. When this value is greater than 2 × 105, the sample is interpreted as positive (+), and when this value is less than or equal to 2 × 105, the sample is interpreted as negative (−). The left side shows the SARS-CoV-2 variant and its CT value. The right side shows the positive (+) or negative (−) result. f The results of the NGS and CRISPR/Cas12a were consistent with those of the corresponding SNV crRNA and WT crRNA for the detection of the SARS-CoV-2 variants XBB (n = 30) and BA.5.2 (n = 30). True-positive and true-negative percentage agreements are shown in parentheses.
